Inmagene Biopharmaceuticals and HUTCHMED (China) have dosed the first participant in a global Phase I trial of OX40 antagonistic monoclonal antibody, IMG-007. The multi-stage trial is recruiting healthy participants and adult patients with moderate-to-severe atopic dermatitis.
The double-blind, placebo-controlled, randomised, dose-escalation Phase I study has been designed to assess IMG-007’s tolerability, safety, and efficacy. It is a dose-escalation and parallel design, multiple-dose study.
IMG-007 targets the OX40 receptor, a costimulatory receptor member of the tumour necrosis factor receptor (TNFR) superfamily expressed predominantly on activated T cells.
Originally, it was originally discovered by HUTCHMED and later Inmagene assumed the development responsibility at the candidate stage.
Inmagene holds an exclusive option to in-license global rights of the antibody.
Inmagene chief development officer Dr Jean-Louis Saillot said: “IMG-007 blocks the OX40 activity and has demonstrated high potency in preclinical studies, indicating a best-in-class potential.
“We welcome the start of the IMG-007 clinical programme with the hope of developing an innovative, safe and effective treatment option for patients with atopic dermatitis and other immunological diseases.”
Inmagene chairman and CEO Dr Jonathan Wang said: “Dosing the first participant is an important milestone for the IMG-007 programme.
“We hope the data will help us demonstrate that IMG-007 is one of the strongest OX40 antagonist drug candidates worldwide.”
In May this year, Inmagene received the US Food and Drug Administration (FDA) clearance for its drug candidate, IMG-004, to be investigated in a Phase I clinical trial.